BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 208.9 USD | +3.18% |
|
+7.47% | -19.27% |
| Apr. 26 | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
| Apr. 25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 53,543 | 37,679 | 35,242 | 39,877 | 37,495 | 30,415 | - | - |
| Enterprise Value (EV) 1 | 51,733 | 41,723 | 37,820 | 40,560 | 43,384 | 33,795 | 30,764 | 27,056 |
| P/E ratio | 9.44 x | 9.87 x | 23.1 x | 13.3 x | 32.5 x | 15.9 x | 13.8 x | 11.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.72 x | 2.8 x | 3.21 x | 3.92 x | 3.81 x | 3.19 x | 3.19 x | 3.08 x |
| EV / Revenue | 3.6 x | 3.1 x | 3.44 x | 3.99 x | 4.41 x | 3.55 x | 3.23 x | 2.74 x |
| EV / EBITDA | 6.41 x | 5.56 x | 9.13 x | 11.2 x | 14.3 x | 10 x | 8.42 x | 6.58 x |
| EV / FCF | 7.88 x | 11 x | 11.2 x | 35.5 x | 34.2 x | 14.7 x | 11.1 x | 9.18 x |
| FCF Yield | 12.7% | 9.12% | 8.94% | 2.82% | 2.93% | 6.81% | 9.02% | 10.9% |
| Price to Book | 3.87 x | 3.7 x | 3.26 x | 3.02 x | 2.53 x | 1.77 x | 1.56 x | 1.37 x |
| Nbr of stocks (in thousands) | 180,442 | 153,882 | 146,893 | 144,001 | 144,898 | 145,597 | - | - |
| Reference price 2 | 296.7 | 244.9 | 239.9 | 276.9 | 258.8 | 208.9 | 208.9 | 208.9 |
| Announcement Date | 1/30/20 | 2/3/21 | 2/3/22 | 2/15/23 | 2/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 14,378 | 13,445 | 10,982 | 10,173 | 9,836 | 9,524 | 9,538 | 9,859 |
| EBITDA 1 | 8,070 | 7,504 | 4,144 | 3,618 | 3,040 | 3,371 | 3,653 | 4,112 |
| EBIT 1 | 7,390 | 6,837 | 3,656 | 3,099 | 2,545 | 2,858 | 3,074 | 3,332 |
| Operating Margin | 51.4% | 50.85% | 33.3% | 30.47% | 25.87% | 30.01% | 32.23% | 33.8% |
| Earnings before Tax (EBT) 1 | 7,126 | 5,048 | 1,745 | 3,592 | 1,297 | 2,266 | 2,786 | 3,423 |
| Net income 1 | 5,888 | 4,001 | 1,556 | 3,047 | 1,161 | 1,894 | 2,217 | 2,653 |
| Net margin | 40.96% | 29.76% | 14.17% | 29.95% | 11.8% | 19.89% | 23.24% | 26.91% |
| EPS 2 | 31.42 | 24.80 | 10.40 | 20.87 | 7.970 | 13.13 | 15.14 | 18.39 |
| Free Cash Flow 1 | 6,564 | 3,805 | 3,382 | 1,144 | 1,270 | 2,300 | 2,776 | 2,949 |
| FCF margin | 45.65% | 28.3% | 30.8% | 11.25% | 12.91% | 24.15% | 29.1% | 29.91% |
| FCF Conversion (EBITDA) | 81.34% | 50.71% | 81.61% | 31.62% | 41.79% | 68.24% | 76% | 71.71% |
| FCF Conversion (Net income) | 111.47% | 95.11% | 217.34% | 37.55% | 109.4% | 121.44% | 125.2% | 111.13% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 1/30/20 | 2/3/21 | 2/3/22 | 2/15/23 | 2/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,734 | 2,532 | 2,589 | 2,508 | 2,544 | 2,463 | 2,456 | 2,530 | 2,386 | 2,290 | 2,378 | 2,404 | 2,448 | 2,365 | 2,413 |
| EBITDA 1 | 780.7 | 844.1 | 1,112 | 991 | 792.7 | 674.7 | 797.7 | 853.1 | 697.5 | 795.5 | 956.5 | 981.6 | 1,024 | - | - |
| EBIT 1 | 646 | 708.6 | 976.7 | 870 | 672.9 | 467.5 | 674.2 | 728.1 | 557.4 | 648 | 709.6 | 731.9 | 726.5 | 718.1 | 751.9 |
| Operating Margin | 23.63% | 27.99% | 37.72% | 34.68% | 26.45% | 18.98% | 27.45% | 28.78% | 23.36% | 28.29% | 29.84% | 30.44% | 29.68% | 30.37% | 31.15% |
| Earnings before Tax (EBT) 1 | 405 | 347.4 | 1,270 | 1,371 | 603.8 | 438.3 | 708.1 | -141.2 | 291.6 | 464.8 | 627.3 | 545 | 549.5 | 512.5 | 526.5 |
| Net income 1 | 368.2 | 303.8 | 1,058 | 1,135 | 550.4 | 387.9 | 591.6 | -68.1 | 249.7 | 393.4 | 524.2 | 480.2 | 488.6 | 458 | 488.3 |
| Net margin | 13.47% | 12% | 40.86% | 45.23% | 21.64% | 15.75% | 24.09% | -2.69% | 10.47% | 17.18% | 22.04% | 19.97% | 19.96% | 19.37% | 20.23% |
| EPS 2 | 2.500 | 2.060 | 7.240 | 7.840 | 3.790 | 2.670 | 4.070 | -0.4700 | 1.710 | 2.700 | 3.587 | 3.176 | 3.351 | 3.290 | 3.405 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/3/22 | 5/3/22 | 7/20/22 | 10/25/22 | 2/15/23 | 4/25/23 | 7/25/23 | 11/8/23 | 2/13/24 | 4/24/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 4,044 | 2,578 | 683 | 5,888 | 3,380 | 349 | - |
| Net Cash position 1 | 1,810 | - | - | - | - | - | - | 3,359 |
| Leverage (Debt/EBITDA) | - | 0.5389 x | 0.6221 x | 0.1888 x | 1.937 x | 1.003 x | 0.0954 x | - |
| Free Cash Flow 1 | 6,564 | 3,805 | 3,382 | 1,144 | 1,270 | 2,300 | 2,776 | 2,949 |
| ROE (net income / shareholders' equity) | 47.7% | 45.2% | 26.6% | 21.2% | 15.2% | 14.1% | 14.5% | 14.2% |
| ROA (Net income/ Total Assets) | 24% | 15.4% | 11.9% | 12.6% | 4.52% | 7.56% | 7.57% | 7.86% |
| Assets 1 | 24,583 | 25,927 | 13,124 | 24,216 | 25,699 | 25,041 | 29,272 | 33,763 |
| Book Value Per Share 2 | 76.60 | 66.20 | 73.50 | 91.70 | 102.0 | 118.0 | 134.0 | 153.0 |
| Cash Flow per Share 2 | 38.00 | 26.20 | 24.30 | 9.480 | 10.60 | 15.50 | 20.50 | 26.90 |
| Capex 1 | 515 | 425 | 258 | 240 | 277 | 298 | 289 | 289 |
| Capex / Sales | 3.58% | 3.16% | 2.35% | 2.36% | 2.82% | 3.13% | 3.03% | 2.93% |
| Announcement Date | 1/30/20 | 2/3/21 | 2/3/22 | 2/15/23 | 2/13/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
208.9
USD
Average target price
285.9
USD
Spread / Average Target
+36.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.27% | 30.42B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B | |
| +2.29% | 7.72B |
- Stock Market
- Equities
- BIIB Stock
- Financials Biogen Inc.
